Search results
Search for "acetylcholinesterase" in Full Text gives 31 result(s) in Beilstein Journal of Organic Chemistry.
Total synthesis of natural products based on hydrogenation of aromatic rings
- Haoxiang Wu and
- Xiangbing Qi
Beilstein J. Org. Chem. 2026, 22, 88–122, doi:10.3762/bjoc.22.4
- family have been reported, with some known to exhibit acetylcholinesterase inhibitory activity and other notable bioactivities. Their architecturally complex and unique polycyclic frameworks have attracted sustained interest from synthetic, natural product, and medicinal chemists alike. In 2023, Ishikawa
Graphical Abstract
Scheme 1: The association between dearomatization and natural product synthesis.
Scheme 2: Key challenges in hydrogenation of aromatic rings.
Scheme 3: Hydrogenation of heterocyclic aromatic rings.
Scheme 4: Hydrogenation of the carbocyclic aromatic rings.
Scheme 5: Hydrogenation of the heterocycle part in bicyclic aromatic rings.
Scheme 6: Hydrogenation of the heterocycle part in bicyclic aromatic rings.
Scheme 7: Hydrogenation of benzofuran, indole, and their analogues.
Scheme 8: Hydrogenation of benzofuran, indole, and their analogues.
Scheme 9: Total synthesis of (±)-keramaphidin B by Baldwin and co-workers.
Scheme 10: Total synthesis of (±)-LSD by Vollhardt and co-workers.
Scheme 11: Total synthesis of (±)-dihydrolysergic acid by Boger and co-workers.
Scheme 12: Total synthesis of (±)-lysergic acid by Smith and co-workers.
Scheme 13: Hydrogenation of (−)-tabersonine to (−)-decahydrotabersonine by Catherine Dacquet and co-workers.
Scheme 14: Total synthesis of (±)-nominine by Natsume and co-workers.
Scheme 15: Total synthesis of (+)-nominine by Gin and co-workers.
Scheme 16: Total synthesis of (±)-lemonomycinone and (±)-renieramycin by Magnus.
Scheme 17: Total synthesis of GB13 by Sarpong and co-workers.
Scheme 18: Total synthesis of GB13 by Shenvi and co-workers.
Scheme 19: Total synthesis of (±)-corynoxine and (±)-corynoxine B by Xia and co-workers.
Scheme 20: Total synthesis of (+)-serratezomine E and the putative structure of huperzine N by Bonjoch and co-...
Scheme 21: Total synthesis of (±)-serralongamine A and the revised structure of huperzine N and N-epi-huperzin...
Scheme 22: Early attempts to indenopiperidine core.
Scheme 23: Homogeneous hydrogenation and completion of the synthesis.
Scheme 24: Total synthesis of jorunnamycin A and jorumycin by Stoltz and co-workers.
Scheme 25: Early attempt towards (−)-finerenone by Aggarwal and co-workers.
Scheme 26: Enantioselective synthesis towards (−)-finerenone.
Scheme 27: Total synthesis of (+)-N-methylaspidospermidine by Smith, Grigolo and co-workers.
Scheme 28: Dearomatization approach towards matrine-type alkaloids.
Scheme 29: Asymmetric total synthesis to (−)-senepodine F via an asymmetric hydrogenation of pyridine.
Scheme 30: Selective hydrogenation of indole derivatives and application.
Scheme 31: Synthetic approaches to the oxindole alkaloids by Qi and co-workers.
Scheme 32: Total synthesis of annotinolide B by Smith and co-workers.
Comparative analysis of complanadine A total syntheses
- Reem Al-Ahmad and
- Mingji Dai
Beilstein J. Org. Chem. 2025, 21, 2334–2344, doi:10.3762/bjoc.21.178
- molecules such as the huperzines have been discovered and advanced into human clinical trials as acetylcholinesterase inhibitors for treating Alzheimer’s disease [3]. Among the lycopodium family, complanadine A (1, Scheme 1) and its natural congeners such as complanadines B (2), D (3), and E (4) were
Graphical Abstract
Scheme 1: Complanadine natural products and their plausible biosynthesis.
Scheme 2: The Siegel total synthesis of complanadine A enabled by [2 + 2 + 2] cycloadditions.
Scheme 3: The Sarpong total synthesis of complanadine A enabled by a biomimetic strategy and C–H activation.
Scheme 4: The Tsukano total synthesis of complanadine A enabled by Diels–Alder cycloaddition, Heck cyclizatio...
Scheme 5: The Dai total synthesis of complanadine A using single-atom skeletal editing.
Scheme 6: Comparative summary of the four complanadine A total syntheses.
Research progress on calixarene/pillararene-based controlled drug release systems
- Liu-Huan Yi,
- Jian Qin,
- Si-Ran Lu,
- Liu-Pan Yang,
- Li-Li Wang and
- Huan Yao
Beilstein J. Org. Chem. 2025, 21, 1757–1785, doi:10.3762/bjoc.21.139
- vesicles, with the hydrophobic alkyl chains of myristoylcholine packing together and the inner and outer surfaces composed of the hydrophilic phenolic OH groups of SC4A exposed to the aqueous solution. Subsequently, cholinesterase (acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)) specifically
Graphical Abstract
Figure 1: Schematic diagram of drug-controlled release mechanisms based on aromatic macrocycles.
Figure 2: Chemical structure of a) calix[n]arene (m = 1,3,5), and b) pillar[n]arene (m = 1,2,3).
Figure 3: Changes in pH conditions cause the release of drugs from CA8 host–guest complexes [101]. Figure 3 was adapted wi...
Figure 4: The illustration of the pH-mediated 1:1 complex formation between the host and guest molecules in a...
Figure 5: Illustration of the pH-responsive self-assembly of mannose-modified CA4 into micelles and the subse...
Figure 6: Illustration of the assembly of supramolecular prodrug nanoparticles from WP6 and DOX-derived prodr...
Figure 7: Illustration of the formation of supramolecular vesicles and their pH-dependent drug release [93]. Figure 7 was...
Figure 8: Schematic illustration of the application of the multifunctional nanoplatform CyCA@POPD in combined...
Figure 9: Illustration of the photolysis of an amphiphilic assembly via CA-induced aggregation [114]. Figure 9 was reprint...
Figure 10: Schematic illustration of drug release controlled by the photo-responsive macroscopic switch based ...
Figure 11: Schematic illustration of the formation process of Azo-SMX and its photoisomerization reaction unde...
Figure 12: Schematic illustration of the enzyme-responsive behavior of supramolecular polymers [95]. Figure 12 was used wit...
Figure 13: Schematic illustration of the amphiphilic assembly of SC4A and its enzyme-responsive applications [119]. ...
Figure 14: Stimuli-responsive nanovalves based on MSNs and choline-SC4A[2]pseudorotaxanes, MSN-C1 with ester-l...
Figure 15: A schematic diagram showing the construction of a supramolecular system by host–guest interaction b...
Figure 16: A schematic diagram showing the formation of the host–guest complex DOX@Biotin-SAC4A by biotin modi...
Figure 17: A schematic diagram showing the self-assembly of CA4 into a hypoxia-responsive peptide hydrogel, wh...
Figure 18: Schematic illustration of the formation process of Lip@GluAC4A and the release of Lip under hypoxic...
Figure 19: Schematic illustration of the construction of a supramolecular vesicle based on the host–guest comp...
Figure 20: Schematic illustration of WP6 self-assembly at pH > 7, and the stimulus-responsive drug release beh...
Figure 21: Schematic illustration of the formation of supramolecular vesicles based on the WP5⊃G super-amphiph...
Figure 22: Schematic illustrations of the host–guest recognition of QAP5⊃SXD, the formation of the nanoparticl...
Figure 23: Schematic illustration of the activation of T-SRNs by acid, alkali, or Zn2+ stimuli to regulate the...
Figure 24: Illustration of the triggered release of BH from CP[5]A@MSNs-Q NPs in response to a drop in pH or a...
Figure 25: Illustration of the supramolecular amphiphiles TPENCn@1 (n = 6 and 12) self-assembling with disulfi...
Recent total synthesis of natural products leveraging a strategy of enamide cyclization
- Chun-Yu Mi,
- Jia-Yuan Zhai and
- Xiao-Ming Zhang
Beilstein J. Org. Chem. 2025, 21, 999–1009, doi:10.3762/bjoc.21.81
- acetylcholinesterase (AChE) inhibitory activities [18]. In the presence of a catalytic amount of PPh3AuCl and AgSbF6, the enamide–alkyne cycloisomerization of bromo-substituted alkyne 8 proceeded via a 5-endo-dig cyclization to afford tricyclic compound 10 through the formation of iminium intermediate 9. The azepane
Graphical Abstract
Figure 1: Reactivity of enamides and enamide cyclizations.
Scheme 1: Total synthesis of (−)-dihydrolycopodine and (−)-lycopodine.
Scheme 2: Collective total synthesis of fawcettimine-type alkaloids.
Scheme 3: Total syntheses of cephalotaxine and cephalezomine H.
Scheme 4: Collective total syntheses of Cephalotaxus alkaloids.
Scheme 5: Asymmetric tandem cyclization/Pictet–Spengler reaction of tertiary enamides.
Scheme 6: Tandem cyclization/Pictet–Spengler reaction for the synthesis of chiral tetracyclic compounds.
Scheme 7: Total synthesis of (−)-cephalocyclidin A.
Origami with small molecules: exploiting the C–F bond as a conformational tool
- Patrick Ryan,
- Ramsha Iftikhar and
- Luke Hunter
Beilstein J. Org. Chem. 2025, 21, 680–716, doi:10.3762/bjoc.21.54
Graphical Abstract
Figure 1: Fundamental characteristics of the C–F bond.
Figure 2: Incorporation of fluorine at the end of an alkyl chain.
Figure 3: Incorporation of fluorine into the middle of a linear alkyl chain.
Figure 4: Incorporation of fluorine across much, or all, of a linear alkyl chain.
Figure 5: Incorporation of fluorine into cycloalkanes.
Figure 6: Conformational effects of introducing fluorine into an ether (geminal to oxygen).
Figure 7: Conformational effects of introducing fluorine into an ether (vicinal to oxygen).
Figure 8: Effects of introducing fluorine into alcohols (and their derivatives).
Figure 9: Controlling the ring pucker of sugars through fluorination.
Figure 10: Controlling bond rotations outside the sugar ring through fluorination.
Figure 11: Effects of incorporating fluorine into amines.
Figure 12: Effects of incorporating fluorine into amine derivatives, such as amides and sulfonamides.
Figure 13: Effects of incorporating fluorine into organocatalysts.
Figure 14: Effects of incorporating fluorine into carbonyl compounds, focusing on the “carbon side.”
Figure 15: Fluoroproline-containing peptides and proteins.
Figure 16: Further examples of fluorinated linear peptides (besides fluoroprolines). For clarity, sidechains a...
Figure 17: Fluorinated cyclic peptides.
Figure 18: Fluorine-derived conformational control in sulfur-containing compounds.
Total synthesis of (±)-simonsol C using dearomatization as key reaction under acidic conditions
- Xiao-Yang Bi,
- Xiao-Shuai Yang,
- Shan-Shan Chen,
- Jia-Jun Sui,
- Zhao-Nan Cai,
- Yong-Ming Chuan and
- Hong-Bo Qin
Beilstein J. Org. Chem. 2025, 21, 601–606, doi:10.3762/bjoc.21.47
- synapse growth and inhibits acetylcholinesterase. (±)-Simonsol C (Figure 1) has received considerable attention due to the presence of an aryl- and allyl-containing quaternary carbon center, which is common in natural products such as galanthamine and morphine. To construct the quaternary carbon in
Graphical Abstract
Figure 1: Representative sesquineolignan compounds.
Scheme 1: The first total synthesis of (±)-simonsol C by Banwell’s group.
Scheme 2: The second total synthesis of (±)-simonsol C developed by the Qin group.
Figure 2: Retrosynthetic analysis of (±)-simonsol C.
Scheme 3: Rapid access of the basic skeleton of (±)- simonsol C.
Scheme 4: Synthetic details to (±)-simonsol C.
Multicomponent reactions driving the discovery and optimization of agents targeting central nervous system pathologies
- Lucía Campos-Prieto,
- Aitor García-Rey,
- Eddy Sotelo and
- Ana Mallo-Abreu
Beilstein J. Org. Chem. 2024, 20, 3151–3173, doi:10.3762/bjoc.20.261
- acetylcholinesterase (AChE) on ACh. Among the five drugs prescribed for AD, four (donepezil, rivastigmine, galantamine, and tacrine) are built upon the cholinergic hypothesis [26]. In contrast, memantine emerges as the only drug available that targets the glutamatergic system for AD, functioning as a non-competitive
- concentrations in the later stages of this pathology, has been gaining attention for the treatment of this disease. In 2021, Brandão et al. [33] developed a series of molecules inspired by the oxoindole-β-lactam core, a structural motif, present in many acetylcholinesterase inhibitor drugs, through the Ugi
- paralysis rate of worms (Figure 4). Specifically, they exhibited a percentage of paralysis inhibition of 67%, 47%, 57%, 42%, 45%, and 64%, respectively, which indicates their potential in inhibiting β-amyloid toxicity in AD. These compounds were selected to assess their potential as acetylcholinesterase
Graphical Abstract
Figure 1: Classical MCRs.
Figure 2: Different scaffolds that can be formed with the Ugi adduct.
Scheme 1: Oxoindole-β-lactam core produced in a U4C-3CR.
Figure 3: Most active oxoindole-β-lactam compounds developed by Brãndao et al. [33].
Scheme 2: Ugi-azide synthesis of benzofuran, pyrazole and tetrazole hybrids.
Figure 4: The most promising hybrids synthesized via the Ugi-azide multicomponent reaction reported by Kushwa...
Scheme 3: Four-component Ugi reaction for the synthesis of novel antioxidant compounds.
Figure 5: Most potent antioxidant compounds obtained through the Ugi four-component reaction developed by Pac...
Scheme 4: Four-component Ugi reaction to synthesize β-amiloyd aggregation inhibitors.
Figure 6: The most potential β-amiloyd aggregation inhibitors generated by Galante et al. [37].
Scheme 5: Four-component Ugi reaction to obtain FATH hybrids and the best candidate synthesized.
Scheme 6: Four-component Ugi reaction for the synthesis of FATMH hybrids and the best candidate synthesized.
Scheme 7: Petasis multicomponent reaction to produce pyrazine-based MTDLs.
Figure 7: Best pyrazine-based MTDLs synthesized by Madhav et al. [40].
Scheme 8: Synthesis of BCPOs employing a Knoevenagel-based multicomponent reaction and the best candidate syn...
Scheme 9: Hantzsch multicomponent reaction for the synthesis of DHPs as novel MTDLs.
Figure 8: Most active 1,4-dihydropyridines developed by Malek et al. [43].
Scheme 10: Chromone–donepezil hybrid MTDLs obtained via the Passerini reaction.
Figure 9: Best CDH-based MTDLs as AChE inhibitors synthesized by Malek et al. [46].
Scheme 11: Replacement of the nitrogen in lactams 11 with an oxygen in 12 to influence hydrogen-bond donating ...
Scheme 12: MCR 3 + 2 reaction to develop spirooxindole, spiroacenaphthylene, and bisbenzo[b]pyran compounds.
Figure 10: SIRT2 activity of best derivatives obtained by Hasaninejad et al. [49].
Scheme 13: Synthesis of ML192 analogs using the Gewald multicomponent reaction and the best candidate synthesi...
Scheme 14: Development of 1,5-benzodiazepines via Ugi/deprotection/cyclization (UDC) approach by Xu et al. [59].
Scheme 15: Synthesis of polysubstituted 1,4-benzodiazepin-3-ones using UDC strategy.
Scheme 16: Synthetic procedure to obtain 3-carboxamide-1,4-benzodiazepin-5-ones employing Ugi–reduction–cycliz...
Scheme 17: Ugi cross-coupling (U-4CRs) to synthesize triazolobenzodiazepines.
Scheme 18: Azido-Ugi four component reaction cyclization to obtain imidazotetrazolodiazepinones.
Scheme 19: Synthesis of oxazolo- and thiazolo[1,4]benzodiazepine-2,5-diones via Ugi/deprotection/cyclization a...
Scheme 20: General synthesis of 2,3-dichlorophenylpiperazine-derived compounds by the Ugi reaction and Ugi/dep...
Figure 11: Best DRD2 compounds synthesized using a multicomponent strategy.
Scheme 21: Bucherer–Bergs multicomponent reaction to obtain a key intermediate in the synthesis of pomaglumeta...
Scheme 22: Ugi reaction to synthesize racetam derivatives and example of two racetams synthesized by Cioc et a...
Natural resorcylic lactones derived from alternariol
- Joachim Podlech
Beilstein J. Org. Chem. 2024, 20, 2171–2207, doi:10.3762/bjoc.20.187
- [171], Hyalodendriella sp. [172], Paraconiothyrium sporulosum [173], Pestalotiopsis uvicola [174], and from Talaromyces amestolkiae [175]. Graphislactone A showed moderate activity against acetylcholinesterase (AChE) with an IC50 value of 8.1 μg/mL [167] and is a scavenger for the 2,2-diphenyl-1
Graphical Abstract
Figure 1: Examples of compounds covered in this review categorized in six sub-classes (see text).
Figure 2: Examples of compounds not covered in this review.
Figure 3: Wrongly assigned and thus obsolete structures (details will be discussed in the respective chapters...
Figure 4: Alternariol with the correct IUPAC numbering and an occasionally used numbering based on the biphen...
Figure 5: Alternariol O-methyl ethers.
Figure 6: Alternariol O-glycosides.
Figure 7: Alternariol O-acetates and O-sulfates.
Figure 8: 2-Hydroxy- and 4-hydroxy-substituted alternariol and its O-methyl ethers.
Figure 9: Chloro- and amino-substituted alternariol and its O-methyl ethers.
Figure 10: Presumed alternariol derivatives with non-canonical substitution pattern.
Figure 11: Alternariol derivatives with the 1-methyl group hydroxylated.
Figure 12: Verrulactones: pseudo-dimeric derivatives of altertenuol and related compounds.
Figure 13: Biaryls formed by reductive lactone opening and/or by decarboxylation.
Figure 14: Altenuene and its diastereomers.
Figure 15: 9-O-Demethylated altenuene diastereomers.
Figure 16: Acetylated and methylated altenuene diastereomers.
Figure 17: Altenuene diastereomers modified with lactic acid, pyruvic acid, or acetone.
Figure 18: Neoaltenuene and related compounds.
Figure 19: Dehydroaltenusin and its derivatives.
Scheme 1: Equilibrium of dehydroaltenusin in polar solvents [278].
Figure 20: Further quinoid derivatives.
Figure 21: Dehydroaltenuenes.
Figure 22: Complex aggregates containing dehydroaltenuene substructures and related compounds.
Figure 23: Dihydroaltenuenes.
Figure 24: Altenuic acids and related compounds.
Figure 25: Cyclopentane- and cyclopentene-fused derivatives.
Figure 26: Cyclopentenone-fused derivatives.
Figure 27: Spiro-fused derivatives and a related ring-opened derivative.
Figure 28: Lactones-fused and lactone-substituted derivatives.
Scheme 2: Biosynthesis of alternariol [324].
Scheme 3: Biosynthesis of alternariol and its immediate successors with the genes involved in the respective ...
Scheme 4: Presumed formation of altenuene and its diastereomers and of botrallin.
Scheme 5: Presumed formation of altenuic acids and related compounds.
Scheme 6: A selection of plausible biosynthetic paths to cyclopenta-fused metabolites. (No stereochemistry is...
Scheme 7: Biomimetic synthesis of alternariol (1) by Harris and Hay [66].
Scheme 8: Total synthesis of alternariol (1) by Subba Rao et al. using a Diels–Alder approach [34].
Scheme 9: Total synthesis of alternariol (1) using a Suzuki strategy by Koch and Podlech [62], improved by Kim et...
Scheme 10: Total synthesis of alternariol (1) using an intramolecular biaryl coupling by Abe et al. [63].
Scheme 11: Total synthesis of altenuene (54) and isoaltenuene (55) by Podlech et al. [249].
Scheme 12: Total synthesis of neoaltenuene (69) by Podlech et al. [35].
Scheme 13: Total synthesis of TMC-264 (79) by Tatsuta et al. [185].
Scheme 14: Total synthesis of cephalosol (99) by Koert et al. [304].
2-Heteroarylethylamines in medicinal chemistry: a review of 2-phenethylamine satellite chemical space
- Carlos Nieto,
- Alejandro Manchado,
- Ángel García-González,
- David Díez and
- Narciso M. Garrido
Beilstein J. Org. Chem. 2024, 20, 1880–1893, doi:10.3762/bjoc.20.163
- affinity to key phenethylamine targets like adrenergic or histamine-type receptors, but also to novel ones such as TAAR1 (trace-amine-associated receptor 1), σ1/2 (sigma receptors 1 and 2), or AChE (acetylcholinesterase). Similar to our previous review, a descriptive, simple scope is presented below to
- 1-[2-thiazol-4-yl-(2-aminoethyl)]-4-N-propylpiperazine derivatives as substrates for acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Compounds 106 and 107 showed good inhibitory potency as multitarget-directed ligands (MTD, Scheme 15). Oxadiazole: In their seminal work, Chiaramonte
Graphical Abstract
Scheme 1: Description of the 2-heteroarylethylamine scope of the present review featuring appropriate heteroa...
Scheme 2: 2-Aminoethylpyridine derivatives with therapeutic activity.
Scheme 3: 2-Aminoethylfuran derivatives with therapeutic activity.
Scheme 4: 2-Aminoethylthiophene derivatives with therapeutic activity, part 1.
Scheme 5: 2-Aminoethylthiophene derivatives with therapeutic activity, part 2.
Scheme 6: 2-Aminoethylthiophene derivatives with therapeutic activity, part 3.
Scheme 7: 2-Aminoethylpyrrole derivatives with therapeutic activity.
Scheme 8: Histamine metabolic pathway.
Scheme 9: 2-Aminoethylimidazole derivatives with therapeutic activity, part 1. Krel is referred as histamine ...
Scheme 10: Conformationally restricted 2-aminoethylimidazole derivatives with therapeutic activity, part 2.
Scheme 11: 2-Aminoethylimidazole derivatives with therapeutic activity, part 3.
Scheme 12: 2-Aminoethylimidazole derivatives with therapeutic activity, part 4.
Scheme 13: 2-Aminoethylpyrazole derivatives with therapeutic activity.
Scheme 14: 2-Aminoethylisoxazole derivatives with therapeutic activity.
Scheme 15: 2-Aminoethylthiazole derivatives with therapeutic activity.
Scheme 16: 2-Aminoethyloxadiazole derivatives with therapeutic activity.
Scheme 17: 2-Aminoethyltriazole derivatives with therapeutic activity.
Scheme 18: 2-Aminoethyloxadiazole derivatives with therapeutic activity.
Syntheses and medicinal chemistry of spiro heterocyclic steroids
- Laura L. Romero-Hernández,
- Ana Isabel Ahuja-Casarín,
- Penélope Merino-Montiel,
- Sara Montiel-Smith,
- José Luis Vega-Báez and
- Jesús Sandoval-Ramírez
Beilstein J. Org. Chem. 2024, 20, 1713–1745, doi:10.3762/bjoc.20.152
- , the compounds demonstrated significant acetylcholinesterase inhibitory activity, with IC50 values ranging from 0.35 to 0.50 µM compared to the reference inhibitor tacrine (IC50 value = 0.29 µM). In 2016, El-Shahawi et al. presented the synthesis of novel spiro 1,3-thiazolidin-4-one derivatives at the
Graphical Abstract
Figure 1: Steroidal spiro heterocycles with remarkable pharmacological activity.
Scheme 1: Synthesis of the spirooxetanone 2. a) t-BuOK, THF, rt, 16%.
Scheme 2: Synthesis of the 17-spirooxetane derivative 7. a) HC≡C(CH2)2CH2OTBDPS, n-BuLi, THF, BF3·Et2O, −78 °...
Scheme 3: Pd-catalyzed carbonylation of steroidal alkynols to produce α-methylene-β-lactones at C-3 and C-17 ...
Scheme 4: Catalyst-free protocol to obtain functionalized spiro-lactones by an intramolecular C–H insertion. ...
Scheme 5: One-pot procedure from dienamides to spiro-β-lactams. a) 1. Ac2O, DMAP, Et3N, CH2Cl2, 2. malononitr...
Scheme 6: Spiro-γ-lactone 20 afforded from 7α-alkanamidoestrone derivative 17. a) HC≡CCH2OTHP, n-BuLi, THF, –...
Scheme 7: Synthesis of the 17-spiro-γ-lactone 23, a key intermediate to obtain spironolactone. a) Ethyl propi...
Scheme 8: Synthetic pathway to obtain 17-spirodihydrofuran-3(2H)-ones from 17-oxosteroids. a) 1-Methoxypropa-...
Scheme 9: One-pot procedure to obtain 17-spiro-2H-furan-3-one compounds. a) NaH, diethyl oxalate, benzene, rt...
Scheme 10: Synthesis of 17-spiro-2H-furan-3-one derivatives. a) RCH=NOH, N-chlorosuccinimide/CHCl3, 99%; b) H2...
Scheme 11: Intramolecular condensation of a γ-acetoxy-β-ketoester to synthesize spirofuranone 37. a) (CH3CN)2P...
Scheme 12: Synthesis of spiro 2,5-dihydrofuran derivatives. a) Allyl bromide, DMF, NaH, 0 °C to rt, 93%; b) G-...
Scheme 13: First reported synthesis of C-16 dispiropyrrolidine derivatives. a) Sarcosine, isatin, MeOH, reflux...
Scheme 14: Cycloadducts 47 with antiproliferative activity against human cancer cell lines. a) 1,4-Dioxane–MeO...
Scheme 15: Spiropyrrolidine compounds generated from (E)-16-arylidene steroids and different ylides. a) Acenap...
Scheme 16: 3-Spiropyrrolidines 52a–c obtained from ketones 50a–c. a) p-Toluenesulfonyl hydrazide, MeOH, rt; b)...
Scheme 17: 16-Spiropyrazolines from 16-methylene-13α-estrone derivatives. a) AgOAc, toluene, rt, 78–81%.
Scheme 18: 6-Spiroimidazolines 57 synthesized by a one-pot multicomponent reaction. a) R3-NC, T3P®, DMSO, 70 °...
Scheme 19: Synthesis of spiro-1,3-oxazolines 60, tested as progesterone receptor antagonist agents. a) CF3COCF3...
Scheme 20: Synthesis of spiro-1,3-oxazolidin-2-ones 63 and 66a,b. a) RNH2, EtOH, 70 °C, 70–90%; b) (CCl3O)2CO,...
Scheme 21: Formation of spiro 1,3-oxazolidin-2-one and spiro 2-substituted amino-4,5-dihydro-1,3-oxazoles from ...
Scheme 22: Synthesis of diastereomeric spiroisoxazolines 74 and 75. a) Ar-C(Cl)=N-OH, DIPEA, toluene, rt, 74 (...
Scheme 23: Spiro 1,3-thiazolidine derivatives 77–79 obtained from 2α-bromo-5α-cholestan-3-one 76. a) 2-aminoet...
Scheme 24: Method for the preparation of derivative 83. a) Benzaldehyde, MeOH, reflux, 77%; b) thioglycolic ac...
Scheme 25: Synthesis of spiro 1,3-thiazolidin-4-one derivatives from steroidal ketones. a) Aniline, EtOH, refl...
Scheme 26: Synthesis of spiro N-aryl-1,3-thiazolidin-4-one derivatives 91 and 92. a) Sulfanilamide, DMF, reflu...
Scheme 27: 1,2,4-Trithiolane dimers 94a–e selectively obtained from carbonyl derivatives. a) LR, CH2Cl2, reflu...
Scheme 28: Spiro 1,2,4-triazolidin-3-ones synthesized from semicarbazones. a) H2O2, CHCl3, 0 °C, 82–85%.
Scheme 29: Steroidal spiro-1,3,4-oxadiazoline 99 obtained in two steps from cholest-5-en-3-one (97). a) NH2NHC...
Scheme 30: Synthesis of spiro-1,3,4-thiadiazoline 101 by cyclization and diacetylation of thiosemicarbazone 100...
Scheme 31: Mono- and bis(1,3,4-thiadiazolines) obtained from estrane and androstane derivatives. a) H2NCSNHNH2...
Scheme 32: Different reaction conditions to synthesize spiro-1,3,2-oxathiaphospholanes 108 and 109.
Scheme 33: Spiro-δ-lactones derived from ADT and epi-ADT as inhibitors of 17β-HSDs. a) CH≡C(CH2)2OTHP, n-BuLi,...
Scheme 34: Spiro-δ-lactams 123a,b obtained in a five-step reaction sequence. a) (R)-(+)-tert-butylsulfinamide,...
Scheme 35: Steroid-coumarin conjugates as fluorescent DHT analogues to study 17-oxidoreductases for androgen m...
Scheme 36: 17-Spiro estradiolmorpholinones 130 bearing two types of molecular diversity. a) ʟ- or ᴅ-amino acid...
Scheme 37: Steroidal spiromorpholinones as inhibitors of enzyme 17β-HSD3. a) Methyl ester of ʟ- or ᴅ-leucine, ...
Scheme 38: Steroidal spiro-morpholin-3-ones achieved by N-alkylation or N-acylation of amino diols 141, follow...
Scheme 39: Straightforward method to synthesize a spiromorpholinone derivative from estrone. a) BnBr, K2CO3, CH...
Scheme 40: Pyrazolo[4,3-e][1,2,4]-triazine derivatives 152–154. a) 4-Aminoantipyrine, EtOH/DMF, reflux, 82%; b...
Scheme 41: One-pot procedure to synthesize spiro-1,3,4-thiadiazine derivatives. a) NH2NHCSCONHR, H2SO4, dioxan...
Scheme 42: 1,2,4-Trioxanes with antimalarial activity. a) 1. O2, methylene blue, CH3CN, 500 W tungsten halogen...
Scheme 43: Tetraoxanes 167 and 168 synthesized from ketones 163, 165 and 166. a) NaOH, iPrOH/H2O, 80 °C, 93%; ...
Scheme 44: 1,2,4,5-Tetraoxanes bearing a steroidal moiety and a cycloalkane. a) 30% H2O2/CH2Cl2/CH3CN, HCl, rt...
Scheme 45: Spiro-1,3,2-dioxaphosphorinanes obtained from estrone derivatives. a) KBH4, MeOH, THF or CH2Cl2; b)...
Scheme 46: Synthesis of steroidal spiro-ε-lactone 183. a) 1. Jones reagent, acetone, 0 °C to rt, 2. ClCOCOCl, ...
Scheme 47: Synthesis of spiro-2,3,4,7-tetrahydrooxepines 185 and 187 derived from mestranol and lynestrenol (38...
Research progress on the pharmacological activity, biosynthetic pathways, and biosynthesis of crocins
- Zhongwei Hua,
- Nan Liu and
- Xiaohui Yan
Beilstein J. Org. Chem. 2024, 20, 741–752, doi:10.3762/bjoc.20.68
- (ROSs) [28]. Crocins can inhibit the activity of acetylcholinesterase and increase the acetylcholine concentration, thus improving the learning and memory ability of the brain [29]. Moreover, crocins prevent the abnormal aggregation of amyloid β-protein (Aβ), microtubule-associated protein tau, and α
Graphical Abstract
Figure 1: Principal structure of crocin and crocetin derivatives, including common substituents of the crocet...
Figure 2: The pharmacological activity and mechanisms of action of crocins.
Figure 3: Crocin biosynthetic pathways in C. sativus and G. jasminoides. Enzyme abbreviations are as follows:...
Five new sesquiterpenoids from agarwood of Aquilaria sinensis
- Hong Zhou,
- Xu-Yang Li,
- Hong-Bin Fang,
- He-Zhong Jiang and
- Yong-Xian Cheng
Beilstein J. Org. Chem. 2023, 19, 998–1007, doi:10.3762/bjoc.19.75
- ]. Previous studies have shown that 2-(2-phenylethyl)chromones and sesquiterpenes are the characteristic and main bioactive components of agarwood [5][6]. Various bioactivities, including neuroactive [4], gastrointestinal modulation [7], cytotoxicity [8], antibacterial [9], antifungal, acetylcholinesterase
- studies, the components from A. sinensis possess various attractive bioactivities, such as anti-inflammatory, anticancer, antirenal fibrosis, and acetylcholinesterase inhibitory effects, which motivate us to assume that compounds with similar skeletons may have the same bioactivities. Therefore, the new
Graphical Abstract
Figure 1: Structures of compounds 1–10.
Figure 2: Key 1H,1H-COSY and HMBC correlations for 1–5.
Figure 3: Key ROESY correlations for 2–5.
Figure 4: The calculated and experimental ECD spectra of 1–5.
NaI/PPh3-catalyzed visible-light-mediated decarboxylative radical cascade cyclization of N-arylacrylamides for the efficient synthesis of quaternary oxindoles
- Dan Liu,
- Yue Zhao and
- Frederic W. Patureau
Beilstein J. Org. Chem. 2023, 19, 57–65, doi:10.3762/bjoc.19.5
- synthesis of (±)-physovenine and (±)-physostigmine alkyl analogues exhibiting inhibitory activity against acetylcholinesterase and butyrylcholinesterase [30][78][79][80][81][82][83][84]. Subsequently, we expanded the scope of this protocol to include a benzamide derived acrylamide 1r. The expected six
Graphical Abstract
Figure 1: Representative natural products and biologically active molecules containing an oxindole moiety [7-13].
Scheme 1: Selected photocatalytic decarboxylative radical cascade reactions of N-arylamides.
Scheme 2: Arylamide substrate scope with isolated yields of products.
Scheme 3: Alkyl radical precursor scope with isolated yields of products.
Scheme 4: Selected mechanistic experiments.
One-pot double annulations to confer diastereoselective spirooxindolepyrrolothiazoles
- Juan Lu,
- Bin Yao,
- Desheng Zhan,
- Zhuo Sun,
- Yun Ji and
- Xiaofeng Zhang
Beilstein J. Org. Chem. 2022, 18, 1607–1616, doi:10.3762/bjoc.18.171
- UMB32 and UMB136 [33][34]. Zhang developed 4-aminoquinolines for the synthesis of fluorinated analogues of acetylcholinesterase (AChE) inhibitors [35] in cascade reactions, such as one-step syntheses of quinolines. Quinolin-4-ols involving histone acetyltransferases (HAT) inhibitors [36][37], as well as
Graphical Abstract
Scheme 1: The diastereoselective synthesis of spirooxindoles through MCRs.
Figure 1: Bioactive Spirooxindole-pyrrolothiazoles.
Scheme 2: The synthesis of spirooxindolepyrrolothiazoles.
Scheme 3: Four-component reaction for the synthesis of compound 5.
Scheme 4: Proposed mechanism for the double [3 + 2] cycloadditions.
Scheme 5: The synthesis of compound 5a with ᴅ- and ʟ-cysteine.
Scheme 6: Two-step (process A) vs cascade (process B) synthesis of 5a. i) 1.0:1.15 of 1a/2, EtOH (0.05 M), 25...
Figure 2: Graphical representation of the green metrics (AE, AEf, CE, RME, OE and MP) analysis for processes ...
Figure 3: Graphical representation of the green metrics (PMI, E-factor, and SI) analysis for processes A and ...
Synthesis of sulfur karrikin bioisosteres as potential neuroprotectives
- Martin Pošta,
- Václav Zima,
- Lenka Poštová Slavětínská,
- Marika Matoušová and
- Petr Beier
Beilstein J. Org. Chem. 2022, 18, 549–554, doi:10.3762/bjoc.18.57
- oxygen with sulfur. In particular, we present synthetic procedures toward bioisosteres of karrikins with one or two sulfur heteroatoms incorporated into the core backbone together with evaluation of their biological activity in inhibition of acetylcholinesterase. Keywords: acetylcholinesterase
- brain of patients suffering with the Parkinson’s and the Alzheimer’s disease, respectively. Therefore, research is focused on the discovery of new drugs protecting acetylcholine and dopamine levels via inhibition of acetylcholinesterase (AChE) and monoamine oxidase (MAO). A promising source of such
- until recently. In 2019 a study of Naidoo et al. [20] reported naturally occurring karrikins as compounds with moderate inhibitory activity against both types of monoamine oxidases (MAO-A and MAO-B) and acetylcholinesterase, while the sulfur bioiostere 3-methyl-2H-thiopyrano[3,4-b]furan-2-one (8) [21
Graphical Abstract
Figure 1: Structures of naturally occurring karrikins.
Scheme 1: i) P4S10, THF; ii) 2-chloropropionyl chloride, Et3N; iii) Ph3P, NaOAc, Ac2O.
Figure 2: Target compounds with highlighted positions of oxygen to sulfur exchange.
Scheme 2: i) Lawesson’s reagent, HMDO, toluene, MW irradiation, 120 °C, 60 min.
Scheme 3: i) P4S10 or Lawesson’s reagent, see table for conditions; ii) 2-chloropropionyl chloride, Et3N, DCM...
Scheme 4: i) LiHMDS, MeI, THF, −78 °C.
Scheme 5: i) a) NaOH, MeOH/H2O, rt, Amberlyst 15 [H+], b) AcOH 70% aq, reflux, 2 h; ii) a) EtOCOCl, pyridine,...
Scheme 6: i) Lawesson’s reagent, HMDO, toluene, MW irradiation (120 °C), 60 min.
Asymmetric organocatalyzed synthesis of coumarin derivatives
- Natália M. Moreira,
- Lorena S. R. Martelli and
- Arlene G. Corrêa
Beilstein J. Org. Chem. 2021, 17, 1952–1980, doi:10.3762/bjoc.17.128
- acetylcholinesterase inhibitors [11][12][13], being LSPN223 the most potent compound (Figure 2). Furthermore, coumarin derivatives have been used as fluorescent probes, laser dyes, fluorescent chemosensors, light absorbers for solar cells, optical brighteners, and organic light emitting diodes (OLEDs) [14][15]. From a
- electron-donating and electron-withdrawing substituents. Additionally, the products were evaluated as acetylcholinesterase (AChE) inhibitors and compound 93d showed a promising activity. Gurubrahaman et al. developed a method for the synthesis of (Z)-2-methylenepyrans 96 through a conjugated addition of 4
- acetylcholinesterase by coumarin derivatives. Michael addition of 4-hydroxycoumarins 1 to α,β‐unsaturated enones 2. Organocatalytic conjugate addition of 4-hydroxycoumarin 1 to α,β-unsaturated aldehydes 2 followed by an IMCR. Synthesis of 3,4-dihydrocoumarin derivatives 10 through decarboxylative and dearomatizative
Graphical Abstract
Figure 1: Coumarin-derived commercially available drugs.
Figure 2: Inhibition of acetylcholinesterase by coumarin derivatives.
Scheme 1: Michael addition of 4-hydroxycoumarins 1 to α,β‐unsaturated enones 2.
Scheme 2: Organocatalytic conjugate addition of 4-hydroxycoumarin 1 to α,β-unsaturated aldehydes 2 followed b...
Scheme 3: Synthesis of 3,4-dihydrocoumarin derivatives 10 through decarboxylative and dearomatizative cascade...
Scheme 4: Total synthesis of (+)-smyrindiol (17).
Scheme 5: Michael addition of 4-hydroxycoumarin (1) to enones 2 through a bifunctional modified binaphthyl or...
Scheme 6: Michael addition of ketones 20 to 3-aroylcoumarins 19 using a cinchona alkaloid-derived primary ami...
Scheme 7: Enantioselective reaction of cyclopent-2-enone-derived MBH alcohols 24 with 4-hydroxycoumarins 1.
Scheme 8: Sequential Michael addition/hydroalkoxylation one-pot approach to annulated coumarins 28 and 30.
Scheme 9: Michael addition of 4-hydroxycoumarins 1 to enones 2 using a binaphthyl diamine catalyst 31.
Scheme 10: Asymmetric Michael addition of 4-hydroxycoumarin 1 with α,β-unsaturated ketones 2 catalyzed by a ch...
Scheme 11: Catalytic asymmetric β-C–H functionalization of ketones via enamine oxidation.
Scheme 12: Enantioselective synthesis of polycyclic coumarin derivatives 37 catalyzed by an primary amine-imin...
Scheme 13: Allylic alkylation reaction between 3-cyano-4-methylcoumarins 39 and MBH carbonates 40.
Scheme 14: Enantioselective synthesis of cyclopropa[c]coumarins 45.
Scheme 15: NHC-catalyzed lactonization of 2-bromoenals 46 with 4-hydroxycoumarin (1).
Scheme 16: NHC-catalyzed enantioselective synthesis of dihydrocoumarins 51.
Scheme 17: Domino reaction of enals 2 with hydroxylated malonate 53 catalyzed by NHC 55.
Scheme 18: Oxidative [4 + 2] cycloaddition of enals 57 to coumarins 56 catalyzed by NHC 59.
Scheme 19: Asymmetric [3 + 2] cycloaddition of coumarins 43 to azomethine ylides 60 organocatalyzed by quinidi...
Scheme 20: Synthesis of α-benzylaminocoumarins 64 through Mannich reaction between 4-hydroxycoumarins (1) and ...
Scheme 21: Asymmetric addition of malonic acid half-thioesters 67 to coumarins 66 using the sulphonamide organ...
Scheme 22: Enantioselective 1,4-addition of azadienes 71 to 3-homoacyl coumarins 70.
Scheme 23: Michael addition/intramolecular cyclization of 3-acylcoumarins 43 to 3-halooxindoles 74.
Scheme 24: Enantioselective synthesis of 3,4-dihydrocoumarins 78 catalyzed by squaramide 73.
Scheme 25: Organocatalyzed [4 + 2] cycloaddition between 2,4-dienals 79 and 3-coumarincarboxylates 43.
Scheme 26: Enantioselective one-pot Michael addition/intramolecular cyclization for the synthesis of spiro[dih...
Scheme 27: Michael/hemiketalization addition enantioselective of hydroxycoumarins (1) to: (a) enones 2 and (b)...
Scheme 28: Synthesis of 2,3-dihydrofurocoumarins 89 through Michael addition of 4-hydroxycoumarins 1 to β-nitr...
Scheme 29: Synthesis of pyrano[3,2-c]chromene derivatives 93 via domino reaction between 4-hydroxycoumarins (1...
Scheme 30: Conjugated addition of 4-hydroxycoumarins 1 to nitroolefins 95.
Scheme 31: Michael addition of 4-hydroxycoumarin 1 to α,β-unsaturated ketones 2 promoted by primary amine thio...
Scheme 32: Enantioselective synthesis of functionalized pyranocoumarins 99.
Scheme 33: 3-Homoacylcoumarin 70 as 1,3-dipole for enantioselective concerted [3 + 2] cycloaddition.
Scheme 34: Synthesis of warfarin derivatives 107 through addition of 4-hydroxycoumarins 1 to β,γ-unsaturated α...
Scheme 35: Asymmetric multicatalytic reaction sequence of 2-hydroxycinnamaldehydes 109 with 4-hydroxycoumarins ...
Scheme 36: Mannich asymmetric addition of cyanocoumarins 39 to isatin imines 112 catalyzed by the amide-phosph...
Scheme 37: Enantioselective total synthesis of (+)-scuteflorin A (119).
On the application of 3d metals for C–H activation toward bioactive compounds: The key step for the synthesis of silver bullets
- Renato L. Carvalho,
- Amanda S. de Miranda,
- Mateus P. Nunes,
- Roberto S. Gomes,
- Guilherme A. M. Jardim and
- Eufrânio N. da Silva Júnior
Beilstein J. Org. Chem. 2021, 17, 1849–1938, doi:10.3762/bjoc.17.126
Graphical Abstract
Scheme 1: Schematic overview of transition metals studied in C–H activation processes.
Scheme 2: (A) Known biological activities related to benzimidazole-based compounds; (B and C) an example of a...
Scheme 3: (A) Known biological activities related to quinoline-based compounds; (B and C) an example of a sca...
Scheme 4: (A) Known biological activities related to sulfur-containing compounds; (B and C) an example of a s...
Scheme 5: (A) Known biological activities related to aminoindane derivatives; (B and C) an example of a scand...
Scheme 6: (A) Known biological activities related to norbornane derivatives; (B and C) an example of a scandi...
Scheme 7: (A) Known biological activities related to aniline derivatives; (B and C) an example of a titanium-...
Scheme 8: (A) Known biological activities related to cyclohexylamine derivatives; (B) an example of an intram...
Scheme 9: (A) Known biologically active benzophenone derivatives; (B and C) photocatalytic oxidation of benzy...
Scheme 10: (A) Known bioactive fluorine-containing compounds; (B and C) vanadium-mediated C(sp3)–H fluorinatio...
Scheme 11: (A) Known biologically active Lythraceae alkaloids; (B) synthesis of (±)-decinine (30).
Scheme 12: (A) Synthesis of (R)- and (S)-boehmeriasin (31); (B) synthesis of phenanthroindolizidines by vanadi...
Scheme 13: (A) Known bioactive BINOL derivatives; (B and C) vanadium-mediated oxidative coupling of 2-naphthol...
Scheme 14: (A) Known antiplasmodial imidazopyridazines; (B) practical synthesis of 41.
Scheme 15: (A) Gold-catalyzed drug-release mechanism using 2-alkynylbenzamides; (B and C) chromium-mediated al...
Scheme 16: (A) Examples of anti-inflammatory benzaldehyde derivatives; (B and C) chromium-mediated difunctiona...
Scheme 17: (A and B) Manganese-catalyzed chemoselective intramolecular C(sp3)–H amination; (C) late-stage modi...
Scheme 18: (A and B) Manganese-catalyzed C(sp3)–H amination; (C) late-stage modification of a leelamine deriva...
Scheme 19: (A) Known bioactive compounds containing substituted N-heterocycles; (B and C) manganese-catalyzed ...
Scheme 20: (A) Known indoles that present GPR40 full agonist activity; (B and C) manganese-catalyzed C–H alkyl...
Scheme 21: (A) Examples of known biaryl-containing drugs; (B and C) manganese-catalyzed C–H arylation through ...
Scheme 22: (A) Known zidovudine derivatives with potent anti-HIV properties; (B and C) manganese-catalyzed C–H...
Scheme 23: (A and B) Manganese-catalyzed C–H organic photo-electrosynthesis; (C) late-stage modification.
Scheme 24: (A) Example of a known antibacterial silylated dendrimer; (B and C) manganese-catalyzed C–H silylat...
Scheme 25: (A and B) Fe-based small molecule catalyst applied for selective aliphatic C–H oxidations; (C) late...
Scheme 26: (A) Examples of naturally occurring gracilioethers; (B) the first total synthesis of gracilioether ...
Scheme 27: (A and B) Selective aliphatic C–H oxidation of amino acids; (C) late-stage modification of proline-...
Scheme 28: (A) Examples of Illicium sesquiterpenes; (B) first chemical synthesis of (+)-pseudoanisatin (80) in...
Scheme 29: (A and B) Fe-catalyzed deuteration; (C) late-stage modification of pharmaceuticals.
Scheme 30: (A and B) Biomimetic Fe-catalyzed aerobic oxidation of methylarenes to benzaldehydes (PMHS, polymet...
Scheme 31: (A) Known tetrahydroquinolines with potential biological activities; (B and C) redox-selective Fe c...
Scheme 32: (A) Known drugs containing a benzofuran unit; (B and C) Fe/Cu-catalyzed tandem O-arylation to acces...
Scheme 33: (A) Known azaindolines that act as M4 muscarinic acetylcholine receptor agonists; (B and C) intramo...
Scheme 34: (A) Known indolinones with anticholinesterase activity; (B and C) oxidative C(sp3)–H cross coupling...
Scheme 35: (A and B) Cobalt-catalyzed C–H alkenylation of C-3-peptide-containing indoles; (C) derivatization b...
Scheme 36: (A) Cobalt-Cp*-catalyzed C–H methylation of known drugs; (B and C) scope of the o-methylated deriva...
Scheme 37: (A) Known lasalocid A analogues; (B and C) three-component cobalt-catalyzed C–H bond addition; (D) ...
Scheme 38: (A and B) Cobalt-catalyzed C(sp2)–H amidation of thiostrepton.
Scheme 39: (A) Known 4H-benzo[d][1,3]oxazin-4-one derivatives with hypolipidemic activity; (B and C) cobalt-ca...
Scheme 40: (A and B) Cobalt-catalyzed C–H arylation of pyrrole derivatives; (C) application for the synthesis ...
Scheme 41: (A) Known 2-phenoxypyridine derivatives with potent herbicidal activity; (B and C) cobalt-catalyzed...
Scheme 42: (A) Natural cinnamic acid derivatives; (B and C) cobalt-catalyzed C–H carboxylation of terminal alk...
Scheme 43: (A and B) Cobalt-catalyzed C–H borylation; (C) application to the synthesis of flurbiprofen.
Scheme 44: (A) Benzothiazoles known to present anticonvulsant activities; (B and C) cobalt/ruthenium-catalyzed...
Scheme 45: (A and B) Cobalt-catalyzed oxygenation of methylene groups towards ketone synthesis; (C) synthesis ...
Scheme 46: (A) Known anticancer tetralone derivatives; (B and C) cobalt-catalyzed C–H difluoroalkylation of ar...
Scheme 47: (A and B) Cobalt-catalyzed C–H thiolation; (C) application in the synthesis of quetiapine (153).
Scheme 48: (A) Known benzoxazole derivatives with anticancer, antifungal, and antibacterial activities; (B and...
Scheme 49: (A and B) Cobalt-catalyzed C–H carbonylation of naphthylamides; (C) BET inhibitors 158 and 159 tota...
Scheme 50: (A) Known bioactive pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives; (B and C) cobalt-catalyzed C–H ...
Scheme 51: (A) Known antibacterial cyclic sulfonamides; (B and C) cobalt-catalyzed C–H amination of propargyli...
Scheme 52: (A and B) Cobalt-catalyzed intramolecular 1,5-C(sp3)–H amination; (C) late-stage functionalization ...
Scheme 53: (A and B) Cobalt-catalyzed C–H/C–H cross-coupling between benzamides and oximes; (C) late-state syn...
Scheme 54: (A) Known anticancer natural isoquinoline derivatives; (B and C) cobalt-catalyzed C(sp2)–H annulati...
Scheme 55: (A) Enantioselective intramolecular nickel-catalyzed C–H activation; (B) bioactive obtained motifs;...
Scheme 56: (A and B) Nickel-catalyzed α-C(sp3)–H arylation of ketones; (C) application of the method using kno...
Scheme 57: (A and B) Nickel-catalyzed C(sp3)–H acylation of pyrrolidine derivatives; (C) exploring the use of ...
Scheme 58: (A) Nickel-catalyzed C(sp3)–H arylation of dioxolane; (B) library of products obtained from biologi...
Scheme 59: (A) Intramolecular enantioselective nickel-catalyzed C–H cycloalkylation; (B) product examples, inc...
Scheme 60: (A and B) Nickel-catalyzed C–H deoxy-arylation of azole derivatives; (C) late-stage functionalizati...
Scheme 61: (A and B) Nickel-catalyzed decarbonylative C–H arylation of azole derivatives; (C) application of t...
Scheme 62: (A and B) Another important example of nickel-catalyzed C–H arylation of azole derivatives; (C) app...
Scheme 63: (A and B) Another notable example of a nickel-catalyzed C–H arylation of azole derivatives; (C) lat...
Scheme 64: (A and B) Nickel-based metalorganic framework (MOF-74-Ni)-catalyzed C–H arylation of azole derivati...
Scheme 65: (A) Known commercially available benzothiophene-based drugs; (B and C) nickel-catalyzed C–H arylati...
Scheme 66: (A) Known natural tetrahydrofuran-containing substances; (B and C) nickel-catalyzed photoredox C(sp3...
Scheme 67: (A and B) Another notable example of a nickel-catalyzed photoredox C(sp3)–H alkylation/arylation; (...
Scheme 68: (A) Electrochemical/nickel-catalyzed C–H alkoxylation; (B) achieved scope, including three using na...
Scheme 69: (A) Enantioselective photoredox/nickel catalyzed C(sp3)–H arylation; (B) achieved scope, including ...
Scheme 70: (A) Known commercially available trifluoromethylated drugs; (B and C) nickel-catalyzed C–H trifluor...
Scheme 71: (A and B) Stereoselective nickel-catalyzed C–H difluoroalkylation; (C) late-stage functionalization...
Scheme 72: (A) Cu-mediated ortho-amination of oxalamides; (B) achieved scope, including derivatives obtained f...
Scheme 73: (A) Electro-oxidative copper-mediated amination of 8-aminoquinoline-derived amides; (B) achieved sc...
Scheme 74: (A and B) Cu(I)-mediated C–H amination with oximes; (C) derivatization using telmisartan (241) as s...
Scheme 75: (A and B) Cu-mediated amination of aryl amides using ammonia; (C) late-stage modification of proben...
Scheme 76: (A and B) Synthesis of purine nucleoside analogues using copper-mediated C(sp2)–H activation.
Scheme 77: (A) Copper-mediated annulation of acrylamide; (B) achieved scope, including the synthesis of the co...
Scheme 78: (A) Known bioactive compounds containing a naphthyl aryl ether motif; (B and C) copper-mediated eth...
Scheme 79: (A and B) Cu-mediated alkylation of N-oxide-heteroarenes; (C) late-stage modification.
Scheme 80: (A) Cu-mediated cross-dehydrogenative coupling of polyfluoroarenes and alkanes; (B) scope from know...
Scheme 81: (A) Known anticancer acrylonitrile compounds; (B and C) Copper-mediated cyanation of unactivated al...
Scheme 82: (A) Cu-mediated radiofluorination of 8-aminoquinoline-derived aryl amides; (B) achieved scope, incl...
Scheme 83: (A) Examples of natural β-carbolines; (B and C) an example of a zinc-catalyzed C–H functionalizatio...
Scheme 84: (A) Examples of anticancer α-aminophosphonic acid derivatives; (B and C) an example of a zinc-catal...
Vicinal difluorination as a C=C surrogate: an analog of piperine with enhanced solubility, photostability, and acetylcholinesterase inhibitory activity
- Yuvixza Lizarme-Salas,
- Alexandra Daryl Ariawan,
- Ranjala Ratnayake,
- Hendrik Luesch,
- Angela Finch and
- Luke Hunter
Beilstein J. Org. Chem. 2020, 16, 2663–2670, doi:10.3762/bjoc.16.216
- difluoroalkane moiety. We show that this fluorinated analog of piperine has superior physicochemical properties, and it also has higher potency and selectivity towards one particular drug target, acetylcholinesterase. This work highlights the potential usefulness of the threo-difluoroalkane motif as a surrogate
- carried out, and these studies have led to a diverse array of biological activities being claimed for this compound [4][5][6][7][8][9]. For example, 1 is reported to exhibit inhibitory activity towards both acetylcholinesterase (AChE) and β-secretase (BACE-1), which suggests that 1 could hold promise as a
- described for 1 led to no detectable decomposition (Figure 3, Supporting Information File 1). Biological activity and solubility The biological activities of piperine (1) and the analog 2 were compared using two different assays, namely the inhibition of either acetylcholinesterase (AChE) or β-secretase
Graphical Abstract
Figure 1: The natural product piperine (1) is the inspiration for this work; the crystal structure is shown [14]....
Scheme 1: The attempted synthesis of 6 (a diastereoisomer of 2) via a one-step 1,2-difluorination reaction [24]. ...
Scheme 2: The attempted synthesis of 2 via a stepwise fluorination approach (ether series). THF = tetrahydrof...
Scheme 3: Synthesis of compound 2 via a stepwise fluorination approach (ester series). DIC = diisopropylcarbo...
Figure 2: Conformational analysis of 2 by DFT and NMR. The numbering scheme for NMR spins is given on structu...
Figure 3: Analog 2 has greater stability to UV light than does piperine (1).
Figure 4: Biological activity of piperine (1) and derivative 2. (a) Inihbition of AChE by 1 (IC50 >1000 μM) a...
Installation of -SO2F groups onto primary amides
- Jing Liu,
- Shi-Meng Wang,
- Njud S. Alharbi and
- Hua-Li Qin
Beilstein J. Org. Chem. 2019, 15, 1907–1912, doi:10.3762/bjoc.15.186
- binding sites (Figure 1) [20]. The smallest member of this family, methyl sulfonyl fluoride (MSF), is known as a selective and irreversible inhibitor of acetylcholinesterase (AChE) [21][22]. The sulfonyl fluoride inhibitors NSC 127755 was found for specifically modifying tyrosine-31 of DHFR in chicken
Graphical Abstract
Figure 1: Representative sulfonyl fluoride compounds applied in medicinal chemistry and chemical biology.
Scheme 1: Synthesis background of N-fluorosulfonyl amides and fluorosulfates.
Scheme 2: Screening of the substrate scope of amides. Reaction conditions: a mixture of amides 1 (1.0 mmol), ...
Scheme 3: Amide resonance model and X-ray single crystal structure of 4e (CCDC 1906002).
Scheme 4: The proposed reaction mechanism.
Synthesis of 3-aminocoumarin-N-benzylpyridinium conjugates with nanomolar inhibitory activity against acetylcholinesterase
- Nisachon Khunnawutmanotham,
- Cherdchai Laongthipparos,
- Patchreenart Saparpakorn,
- Nitirat Chimnoi and
- Supanna Techasakul
Beilstein J. Org. Chem. 2018, 14, 2545–2552, doi:10.3762/bjoc.14.231
- 10210, Thailand 10.3762/bjoc.14.231 Abstract A series of 3-amino-6,7-dimethoxycoumarins conjugated with the N-benzylpyridinium moiety through an amide-bond linkage was synthesized and evaluated for their acetylcholinesterase inhibitory activity. A number of the benzylpyridinium derivatives exhibited
- target enzyme by a dual binding site mechanism whereby the coumarin portion binds with the peripheral anionic site while the N-benzylpyridinium residue binds with the catalytic anionic site of the enzyme. Keywords: acetylcholinesterase inhibitor; 3-aminocoumarin; N-benzylpyridinium; dual binding site
- remains incurable; most of the existing treatments only delay the onset or further advancement of AD. Among the current hypotheses for the treatment of AD, inhibition of acetylcholinesterase enzyme (AChE), which is responsible for the degradation of the neurotransmitter acetylcholine (ACh), is the most
Graphical Abstract
Figure 1: Design of the target compounds.
Scheme 1: Synthesis of 3-aminocoumarin-N-benzylpyridinium salts.
Figure 2: Docked conformations of donepezil (ball-and-stick model; pink), compounds 9a, 9b, 9e, 9h, and 9i (s...
Figure 3: Binding interactions in the rhAChE binding pocket with (a) 4a, (b) 9a, (c) 9b, (d) 9e, (e) 9h, (f) ...
Synthesis of 1-indanones with a broad range of biological activity
- Marika Turek,
- Dorota Szczęsna,
- Marek Koprowski and
- Piotr Bałczewski
Beilstein J. Org. Chem. 2017, 13, 451–494, doi:10.3762/bjoc.13.48
- -indanone derivatives 66 were obtained in 13–86% yields (Scheme 22). This method was further applied to the synthesis of biologically active compounds, such as 1-tetralones, 1-benzosuberones and donepezil (a potent acetylcholinesterase inhibitor used in the treatment of Alzheimer’s disease). Halo-1
Graphical Abstract
Figure 1: Biologically active 1-indanones and their structural analogues.
Figure 2: Number of papers about (a) 1-indanones, (b) synthesis of 1-indanones.
Scheme 1: Synthesis of 1-indanone (2) from hydrocinnamic acid (1).
Scheme 2: Synthesis of 1-indanone (2) from 3-(2-bromophenyl)propionic acid (3).
Scheme 3: Synthesis of 1-indanones 5 from 3-arylpropionic acids 4.
Scheme 4: Synthesis of kinamycin (9a) and methylkinamycin C (9b).
Scheme 5: Synthesis of trifluoromethyl-substituted arylpropionic acids 12, 1-indanones 13 and dihydrocoumarin...
Scheme 6: Synthesis of 1-indanones 16 from benzoic acids 15.
Scheme 7: Synthesis of 1-indanones 18 from arylpropionic and 3-arylacrylic acids 17.
Scheme 8: The NbCl5-induced one-step synthesis of 1-indanones 22.
Scheme 9: Synthesis of biologically active 1-indanone derivatives 26.
Scheme 10: Synthesis of enantiomerically pure indatraline ((−)-29).
Scheme 11: Synthesis of 1-indanone (2) from the acyl chloride 30.
Scheme 12: Synthesis of the mechanism-based inhibitors 33 of coelenterazine.
Scheme 13: Synthesis of the indane 2-imidazole derivative 37.
Scheme 14: Synthesis of fluorinated PAHs 41.
Scheme 15: Synthesis of 1-indanones 43 via transition metal complexes-catalyzed carbonylative cyclization of m...
Scheme 16: Synthesis of 6-methyl-1-indanone (46).
Scheme 17: Synthesis of 1-indanone (2) from ester 48.
Scheme 18: Synthesis of benzopyronaphthoquinone 51 from the spiro-1-indanone 50.
Scheme 19: Synthesis of the selective endothelin A receptor antagonist 55.
Scheme 20: Synthesis of 1-indanones 60 from methyl vinyl ketone (57).
Scheme 21: Synthesis of 1-indanones 64 from diethyl phthalate 61.
Scheme 22: Synthesis of 1-indanone derivatives 66 from various Meldrum’s acids 65.
Scheme 23: Synthesis of halo 1-indanones 69.
Scheme 24: Synthesis of substituted 1-indanones 71.
Scheme 25: Synthesis of spiro- and fused 1-indanones 73 and 74.
Scheme 26: Synthesis of spiro-1,3-indanodiones 77.
Scheme 27: Mechanistic pathway for the NHC-catalyzed Stetter–Aldol–Michael reaction.
Scheme 28: Synthesis of 2-benzylidene-1-indanone derivatives 88a–d.
Scheme 29: Synthesis of 1-indanone derivatives 90a–i.
Scheme 30: Synthesis of 1-indanones 96 from o-bromobenzaldehydes 93 and alkynes 94.
Scheme 31: Synthesis of 3-hydroxy-1-indanones 99.
Scheme 32: Photochemical preparation of 1-indanones 103 from ketones 100.
Scheme 33: Synthesis of chiral 3-aryl-1-indanones 107.
Scheme 34: Photochemical isomerization of 2-methylbenzil 108.
Scheme 35: Synthesis of 2-hydroxy-1-indanones 111a–c.
Scheme 36: Synthesis of 1-indanone derivatives 113 and 114 from η6-1,2-dioxobenzocyclobutene complex 112.
Scheme 37: Synthesis of nakiterpiosin (117).
Scheme 38: Synthesis of 2-alkyl-1-indanones 120.
Scheme 39: Synthesis of fluorine-containing 1-indanone derivatives 123.
Scheme 40: Synthesis of 2-benzylidene and 2-benzyl-1-indanones 126, 127 from the chalcone 124.
Scheme 41: Synthesis of 2-bromo-6-methoxy-3-phenyl-1-indanone (130).
Scheme 42: Synthesis of combretastatin A-4-like indanones 132a–s.
Figure 3: Chemical structures of investigated dienones 133 and synthesized cyclic products 134–137.
Figure 4: Chemical structures of 1-indanones and their heteroatom analogues 138–142.
Scheme 43: Synthesis of 2-phosphorylated and 2-non-phosphorylated 1-indanones 147 and 148 from β-ketophosphona...
Scheme 44: Photochemical synthesis of 1-indanone derivatives 150, 153a, 153b.
Scheme 45: Synthesis of polysubstituted-1-indanones 155, 157.
Scheme 46: Synthesis of 1-indanones 159a–g from α-arylpropargyl alcohols 158 using RhCl(PPh3)3 as a catalyst.
Scheme 47: Synthesis of optically active 1-indanones 162 via the asymmetric Rh-catalyzed isomerization of race...
Scheme 48: Mechanism of the Rh-catalyzed isomerization of α-arylpropargyl alcohols 161 to 1-indanones 162.
Figure 5: Chemical structure of abicoviromycin (168) and its new benzo derivative 169.
Scheme 49: Synthesis of racemic benzoabicoviromycin 172.
Scheme 50: Synthesis of [14C]indene 176.
Scheme 51: Synthesis of indanone derivatives 178–180.
Scheme 52: Synthesis of racemic pterosin A 186.
Scheme 53: Synthesis of trans-2,3-disubstituted 1-indanones 189.
Scheme 54: Synthesis of 3-aryl-1-indanone derivatives 192.
Scheme 55: Synthesis of 1-indanone derivatives 194 from 3-(2-iodoaryl)propanonitriles 193.
Scheme 56: Synthesis of 1-indanones 200–204 by cyclization of aromatic nitriles.
Scheme 57: Synthesis of 1,1’-spirobi[indan-3,3’-dione] derivative 208.
Scheme 58: Total synthesis of atipamezole analogues 211.
Scheme 59: Synthesis of 3-[4-(1-piperidinoethoxy)phenyl]spiro[indene-1,1’-indan]-5,5’-diol hydrochloride 216.
Scheme 60: Synthesis of 3-arylindan-1-ones 219.
Scheme 61: Synthesis of 2-hydroxy-1-indanones 222.
Scheme 62: Synthesis of the 1-indanone 224 from the THP/MOM protected chalcone epoxide 223.
Scheme 63: Synthesis of 1-indanones 227 from γ,δ-epoxy ketones 226.
Scheme 64: Synthesis of 2-hydroxy-2-methylindanone (230).
Scheme 65: Synthesis of 1-indanone derivatives 234 from cyclopropanol derivatives 233.
Scheme 66: Synthesis of substituted 1-indanone derivatives 237.
Scheme 67: Synthesis of 7-methyl substituted 1-indanone 241 from 1,3-pentadiene (238) and 2-cyclopentenone (239...
Scheme 68: Synthesis of disubstituted 1-indanone 246 from the siloxydiene 244 and 2-cyclopentenone 239.
Scheme 69: Synthesis of 5-hydroxy-1-indanone (250) via the Diels–Alder reaction of 1,3-diene 248 with sulfoxid...
Scheme 70: Synthesis of halogenated 1-indanones 253a and 253b.
Scheme 71: Synthesis of 1-indanones 257 and 258 from 2-bromocyclopentenones 254.
Scheme 72: Synthesis of 1-indanone 261 from 2-bromo-4-acetoxy-2-cyclopenten-1-one (260) and 1,2-dihydro-4-viny...
Scheme 73: Synthesis of 1-indanone 265 from 1,2-dihydro-7-methoxy-4-vinylnaphthalene (262) and bromo-substitut...
Scheme 74: Synthesis of 1-indanone 268 from dihydro-3-vinylphenanthrene 266 and 4-acetoxy-2-cyclopenten-1-one (...
Scheme 75: Synthesis of 1-indanone 271 from phenylselenyl-substituted cyclopentenone 268.
Scheme 76: Synthesis of 1-indanone 272 from the trienone 270.
Scheme 77: Synthesis of the 1-indanone 276 from the aldehyde 273.
Scheme 78: Synthesis of 1-indanones 278 and 279.
Scheme 79: Synthesis of 1-indanone 285 from octa-1,7-diyne (282) and cyclopentenone 239.
Scheme 80: Synthesis of benz[f]indan-1-one (287) from cyclopentenone 239 and o-bis(dibromomethyl)benzene (286)....
Scheme 81: Synthesis of 3-methyl-substituted benz[f]indan-1-one 291 from o-bis(dibromomethyl)benzene (286) and...
Scheme 82: Synthesis of benz[f]indan-1-one (295) from the anthracene epidioxide 292.
Scheme 83: Synthesis of 1-indanone 299 from homophthalic anhydride 298 and cyclopentynone 297.
Scheme 84: Synthesis of cyano-substituted 1-indanone derivative 301 from 2-cyanomethylbenzaldehyde (300) and c...
Scheme 85: Synthesis of 1-indanone derivatives 303–305 from ketene dithioacetals 302.
Scheme 86: Synthesis of 1-indanones 309–316.
Scheme 87: Mechanism of the hexadehydro-Diels–Alder (HDDA) reaction.
Scheme 88: Synthesis of 1-indenone 318 and 1-indanones 320 and 321 from tetraynes 317 and 319.
Scheme 89: Synthesis of 1-indanone 320 from the triyn 319.
Scheme 90: Synthesis 1-indanone 328 from 2-methylfuran 324.
Scheme 91: Synthesis of 1-indanones 330 and 331 from furans 329.
Scheme 92: Synthesis of 1-indanone 333 from the cycloadduct 332.
Scheme 93: Synthesis of (S)-3-arylindan-1-ones 335.
Scheme 94: Synthesis of (R)-2-acetoxy-1-indanone 338.
Figure 6: Chemical structures of obtained cyclopenta[α]phenanthrenes 339.
Scheme 95: Synthesis of the benzoindanone 343 from arylacetaldehyde 340 with 1-trimethylsilyloxycyclopentene (...
Structure–efficiency relationships of cyclodextrin scavengers in the hydrolytic degradation of organophosphorus compounds
- Sophie Letort,
- Michaël Bosco,
- Benedetta Cornelio,
- Frédérique Brégier,
- Sébastien Daulon,
- Géraldine Gouhier and
- François Estour
Beilstein J. Org. Chem. 2017, 13, 417–427, doi:10.3762/bjoc.13.45
- scavengers 1–4 were tested for their ability to prevent the inhibition of acetylcholinesterase by the chemical warfare agent soman (Figure 11). The heterodifunctionalized derivatives 1 and 3 were, this time, the most effective compounds. Preincubation of compounds 1 and 3 with soman for 60 minutes reduced
- methyl parathion (0.5 mM). The final concentrations of compounds 2, 4, 2-iodosobenzoic acid (IBA), imidazole and TRIMEB were 0.25 mM. Ability of compounds 1–4 in preventing the inhibition of acetylcholinesterase by soman (GD). Synthetic pathway to derivatives 2 and 3 (Tr = trityl). Synthesis of compound
Graphical Abstract
Figure 1: Structures of G agents.
Figure 2: Scavenger based on a heterodifunctionalized β-cyclodextrin derivative.
Figure 3: Structures of β-cyclodextrin derivatives 2–5.
Figure 4: Structures of pesticides tested.
Scheme 1: Synthetic pathway to derivatives 2 and 3 (Tr = trityl).
Scheme 2: Synthesis of compound 4.
Scheme 3: Synthesis of compound 5 (Tr = trityl).
Figure 5: Hydrolysis of methyl paraoxon (0.5 mM) in the presence of compounds 1, 2, 3 or 2-iodosobenzoic acid...
Figure 6: Hydrolysis of methyl paraoxon (0.5 mM) in the presence of compounds 1, 2, 3 or 2-iodosobenzoic acid...
Figure 7: Hydrolysis of methyl paraoxon (0.5 mM) in the presence of compounds 2, 4, 5 or 2-iodosobenzoic acid...
Figure 8: Hydrolysis of methyl paraoxon (0.5 mM) in the presence of mixtures of compounds 4, 5 with IBA or im...
Figure 9: Influence of the pesticide structure on the hydrolytic efficiency of compound 2 (0.25 mM). Kinetic ...
Figure 10: Influence of TRIMEB, IBA and imidazole on the hydrolysis of methyl parathion (0.5 mM). The final co...
Figure 11: Ability of compounds 1–4 in preventing the inhibition of acetylcholinesterase by soman (GD).
Efficient syntheses of climate relevant isoprene nitrates and (1R,5S)-(−)-myrtenol nitrate
- Sean P. Bew,
- Glyn D. Hiatt-Gipson,
- Graham P. Mills and
- Claire E. Reeves
Beilstein J. Org. Chem. 2016, 12, 1081–1095, doi:10.3762/bjoc.12.103
- sector in generating structure and function diverse O-nitrate esters for use as in vivo NO-donors. In this context particular emphasis has been placed on developing O-nitrate esters as biologically active agents that act on acetylcholinesterase (AChE), amyloid-βx-42 (Aβ42) aggregation, cyclooxygenase-II
Graphical Abstract
Scheme 1: Simplified overview outlining how a small number of different IPNs are synthesised and are able to ...
Scheme 2: Protocols for the synthesis of O-nitrated alcohols using (±)-isoprene epoxide and 2° alcohols as st...
Scheme 3: Attempted synthesis of O-nitrate ester rac-19 and rac-20 synthesis.
Scheme 4: Olah et al. O-nitrated alcohol syntheses of 23–33 using N-nitro-2,4-6-trimethylpyridinium tetrafluo...
Scheme 5: O-nitration study using 22 and the alcohols 34–37.
Scheme 6: Silver nitrate mediated synthesis of 2-oxopropyl nitrate 43.
Scheme 7: Application of isoprene for the synthesis of precursors to IPNs and synthesis via ‘halide for nitra...
Scheme 8: Synthesis of (E)-3-methyl-4-chlorobut-2-en-1-ol ((E)-60) and (Z)-3-methyl-4-chlorobut-2-en-1-ol ((Z...
Scheme 9: Using NOESY interactions to establish the conformations of the C=C bonds within (E)-10 and (Z)-9.
Scheme 10: Synthesis of isoprene nitrates (E)-11 and (Z)-12 from ketone 63.
Scheme 11: Attempted synthesis of rac-8 from O-mesylate rac-71.
Scheme 12: Synthesis of O-nitrate 73 from O-mesylate 72.
Scheme 13: Attempted synthesis of 2° alcohol containing 1° nitrate ester rac-19 and the unexpected synthesis o...
Scheme 14: Synthesis of monoterpene derived (1R,5S)-(−)-myrtenol nitrate 86.
Unconventional application of the Mitsunobu reaction: Selective flavonolignan dehydration yielding hydnocarpins
- Guozheng Huang,
- Simon Schramm,
- Jörg Heilmann,
- David Biedermann,
- Vladimír Křen and
- Michael Decker
Beilstein J. Org. Chem. 2016, 12, 662–669, doi:10.3762/bjoc.12.66
- , our group has developed a hybrid drug combining silibinin with tacrine (a potent acetylcholinesterase inhibitor for treatment of Alzheimer’s disease), which shows neuro- and hepatoprotective effects exceeding the cytoprotective effects of silibinin and effectively counteracts tacrine’s dose-dependent
Graphical Abstract
Figure 1: Structures of silibinin, isosilybin, and silychristin, and hydnocarpin-type flavonolignans.
Figure 2: Synthetic strategy of semi-synthesis of hydnocarpins from silybins [22].
Scheme 1: Synthesis of ester derivatives of silibinin and conversion to hydnocarpin-type compounds. Reaction ...
Figure 3: Putative mechanism of dehydration of flavanonols under Mitsunobu conditions.
Scheme 2: Attempt to dehydrate catechin. Reagents and conditions: a) p-nitrobenzoic acid, Ph3P, DIAD, THF, rt...
Scheme 3: Preparation of hydnocarpin (4) and isohydnocarpin (6) and attempt to dehydrate silydianin A (11). R...
Interactions of cyclodextrins and their derivatives with toxic organophosphorus compounds
- Sophie Letort,
- Sébastien Balieu,
- William Erb,
- Géraldine Gouhier and
- François Estour
Beilstein J. Org. Chem. 2016, 12, 204–228, doi:10.3762/bjoc.12.23
Graphical Abstract
Figure 1: Structure of NOPs.
Figure 2: Examples of structures of NOPs.
Figure 3: Structures of pesticides studied in the literature as guest to form an inclusion complex with CDs.
Figure 4: Structures of pesticides sensitive to the presence of CDs.
Scheme 1: The hydrolysis mechanism of substrate (S) in presence of a cyclodextrin (CD).
Figure 5: Structures of the different stereoisomers of G agents.
Scheme 2: Reaction mechanism of CD accelerated decomposition of organophosphorus compound (PX).
Scheme 3: Proposed degradation mechanism of cyclosarin by β-CD [72].
Figure 6: Schematic representations of β-CD and TRIMEB.
Scheme 4: Synthetic pathways to 6-monosubstituted CD derivatives.
Scheme 5: Synthetic pathways to 2-monosubstituted CD by an iodosobenzoate group.
Scheme 6: Synthetic pathways to 2-monosubstituted CDs with N–OH derivatives.
Scheme 7: Synthetic pathways to 3-monosubstituted CDs.
Scheme 8: Synthetic pathways to 3-homodisubstituted CDs.
Scheme 9: Synthetic pathways to 2,3-heterodisubstituted CDs.
